Literature DB >> 1663712

Alterations of phospholipid metabolites in postmortem brain from patients with Alzheimer's disease.

R Nitsch1, A Pittas, J K Blusztajn, B E Slack, J H Growdon, R J Wurtman.   

Abstract

To test the hypothesis that brain cell membranes degenerate in Alzheimer's disease (AD), we measured the levels of phospholipids, their water-soluble metabolites, and glycerophosphocholine (GPC) cholinephosphodiesterase activity in postmortem brain tissue from patients with AD and age-matched controls. We found significantly higher levels of the phospholipid catabolite GPC in AD brain. In contrast, choline and ethanolamine levels were significantly lower in AD, and phospholipid levels were slightly decreased. Furthermore, in AD the activity of the GPC-degrading enzyme GPC cholinephosphodiesterase was unaltered. Our results indicate that membrane phospholipid catabolism is increased in AD brain. Inasmuch as the tissue levels of initial phospholipid precursors were decreased, we suggest that phospholipid turnover is elevated in this neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663712     DOI: 10.1111/j.1749-6632.1991.tb00200.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

Review 1.  Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens.

Authors:  A A Farooqui; S I Rapoport; L A Horrocks
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

2.  Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.

Authors:  J A Conquer; M C Tierney; J Zecevic; W J Bettger; R H Fisher
Journal:  Lipids       Date:  2000-12       Impact factor: 1.880

3.  1H and 31P magnetic resonance spectroscopic imaging of white matter signal hyperintensity areas in elderly subjects.

Authors:  J M Constans; D J Meyerhoff; D Norman; G Fein; M W Weiner
Journal:  Neuroradiology       Date:  1995-11       Impact factor: 2.804

4.  Neural membrane phospholipids in Alzheimer disease.

Authors:  K Wells; A A Farooqui; L Liss; L A Horrocks
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

Review 5.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

6.  Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain.

Authors:  N Schuff; D L Amend; D J Meyerhoff; J L Tanabe; D Norman; G Fein; M W Weiner
Journal:  Radiology       Date:  1998-04       Impact factor: 11.105

Review 7.  Lipid metabolism in Alzheimer's disease.

Authors:  Qiang Liu; Juan Zhang
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

8.  Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.

Authors:  S MacKay; D J Meyerhoff; J M Constans; D Norman; G Fein; M W Weiner
Journal:  Arch Neurol       Date:  1996-02

9.  CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status.

Authors:  Ruocheng Dong; Burcu F Darst; Yuetiva Deming; Yue Ma; Qiongshi Lu; Henrik Zetterberg; Kaj Blennow; Cynthia M Carlsson; Sterling C Johnson; Sanjay Asthana; Corinne D Engelman
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-01

10.  Lipid, fatty acid, carnitine- and choline derivative profiles in rheumatoid arthritis outpatients with different degrees of periodontal inflammation.

Authors:  Kathrin Beyer; Stein Atle Lie; Bodil Bjørndal; Rolf K Berge; Asbjørn Svardal; Johan G Brun; Anne Isine Bolstad
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.